(Q33260251)

English

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson' (English)

1 reference

Europe PubMed Central

24 July 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

Ubaldo Bonuccelli

object named as

U Bonuccelli

3

0 references

10

object named as

W Poewe

1 reference

Europe PubMed Central

24 July 2017

Andrew John Lees

8

object named as

A Lees

1 reference

Europe PubMed Central

24 July 2017

European Federation of Neurological Societies

13

object named as

European Federation of Neurological Societies

1 reference

Europe PubMed Central

24 July 2017

Wolfgang H. Oertel

9

object named as

W Oertel

1 reference

Europe PubMed Central

24 July 2017

Günther Deuschl

4

object named as

G Deuschl

1 reference

Europe PubMed Central

24 July 2017

Movement Disorder Society-European Section

14

object named as

Movement Disorder Society-European Section

1 reference

Europe PubMed Central

24 July 2017

author name string

M Horstink

1

1 reference

Europe PubMed Central

24 July 2017

E Tolosa

2

1 reference

Europe PubMed Central

24 July 2017

P Kanovsky

6

1 reference

Europe PubMed Central

24 July 2017

J P Larsen

7

1 reference

Europe PubMed Central

24 July 2017

O Rascol

11

1 reference

Europe PubMed Central

24 July 2017

C Sampaio

12

1 reference

Europe PubMed Central

24 July 2017

A Friedman

5

1 reference

Europe PubMed Central

24 July 2017

publication date

1 November 2006

1 reference

Europe PubMed Central

24 July 2017

European Journal of Neurology

1 reference

Europe PubMed Central

24 July 2017

13

1 reference

Europe PubMed Central

24 July 2017

1186-1202

1 reference

Europe PubMed Central

24 July 2017

11

1 reference

Europe PubMed Central

24 July 2017

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Deprenyl in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Levodopa infusion therapy in Parkinson disease: state of the art in 2004.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Low dosages of bromocriptine added to levodopa in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Randomized trial of pallidotomy versus medical therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Neuropsychological and psychiatric sequelae of pallidotomy for PD: clinical trial findings

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. A controlled comparative study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Developmental gene expression and immunohistochemical study of the human endocrine pancreas during fetal life.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Role of surgery in the treatment of motor complications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Cognitive outcomes after deep brain stimulation for Parkinson's disease: a review of initial studies and recommendations for future research

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Declines in switching underlie verbal fluency changes after unilateral pallidal surgery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Behavioural disorders, Parkinson's disease and subthalamic stimulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Suicide after successful deep brain stimulation for movement disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Stereotactic neurosurgery for tremor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Deep brain stimulation is preferable to thalamotomy for tremor suppression.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Efficacy of unilateral deep brain stimulation of the VIM nucleus of the thalamus for essential head tremor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Dorsal subthalamotomy for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Protein redistribution diet remains effective in patients with fluctuating parkinsonism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Cognitive dysfunction and dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Psychiatric aspects of Parkinson's disease--an update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Olanzapine treatment for dopaminergic-induced hallucinations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Do atypical antipsychotics cause stroke?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Risperidone treatment of drug-related psychosis in patients with parkinsonism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Depression and Parkinson's disease: a review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Symptoms and duration of the prodromal phase in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

What contributes to quality of life in patients with Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Altered serotonin metabolism in depressed patients with parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Antidepressant studies in Parkinson's disease: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

SSRIs in the treatment of depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Does Nefazodone Improve Both Depression and Parkinson Disease? A Pilot Randomized Trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared to a realistic sham stimulation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Metoclopramide-induced movement disorders. Clinical findings with a review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Apomorphine-induced penile erections in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01548.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2006.01548.X

1 reference

Europe PubMed Central

24 July 2017

release_ohv5kctcpfa3diu3t2j2rf3sa4

1 reference

https://api.fatcat.wiki/v0/release/ohv5kctcpfa3diu3t2j2rf3sa4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33260251&oldid=1971127357"